UNICREDIT BANK/CALL/BIOGEN IDEC/320/0.1/14.01.26 | Real-time BOERSE MUENCHEN 03:41:15 2024-06-03 EDT | ||
| 2.1 EUR | 0.00% |
|
| 1 month | +39.07% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 2.1 | 0.00% |
| 24-05-31 | 2.1 | +8.81% |
| 24-05-30 | 1.93 | +6.63% |
| 24-05-29 | 1.81 | -3.72% |
| 24-05-28 | 1.88 | -2.08% |
Real-time BOERSE MUENCHEN
Last update June 03, 2024 at 03:41 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD4WFT |
| ISIN | DE000HD4WFT2 |
| Date issued | 2024-04-22 |
| Strike | 320 $ |
| Maturity | 2026-01-14 (591 Days) |
| Parity | 10 : 1 |
| Emission price | 1.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.46 € |
|---|---|
| Lowest since issue | 1.07 € |
| Spread | 0.12 € |
| Spread % | 5.50% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
- Stock Market
- Warrants
- Warrant
